Radiosynthesis and Preliminary in Vivo Studies with [11C]SB216763: the First Brain Penetrative PET Tracer for Imaging of Glycogen Synthase Kinase-3 (GSK-3)
Lei Li,Valentina Ferrari,Young T. Hong,David Williamson,Tim D. Fryer,Franklin I. Aigbirhio
2013-01-01
Journal of Nuclear Medicine
Abstract:324 Objectives Research has shown that the enzyme glycogen synthase kinase-3 (GSK-3) acts as a key component in many cellular and physiological processes, including ones involved in neuropathological conditions[1]. As GSK-3 inhibitors have been recognised as promising therapeutics for neurodegenerative conditions such as Alzheimer’s disease [2], there is a need for a PET tracer to complement their development. Herein, we report the radiosynthesis and preliminary evaluation of carbon-11 labelled SB216763 ((3-(2,4-dichlorophenyl)-4-(1-methyl-1H-indol-3-yl)), a GSK-3 inhibitor with an IC50 value of 34 nM [3], as a potential PET tracer for in vivo assessment of GSK-3. Methods The Zheng group reported the first radiosynthetic method of [11C]SB216763 by [11C]methylation of maleic anhydride intermediate, which was then converted to maleimide [4] However, this radiochemical method could not be reproduced, hence we developed an alternate synthetic route. Since direct [11C]methylation would result in [11C]methylation on the maleimide nitrogen rather than the indole nitrogen due to its lower pKa value, a 2,4-dimethyl benzyl group was introduced as a protecting group. After [11C]methylation of the indole nitrogen, the protecting group was then cleaved in acidic conditions to produce [11C]SB-216763 in one pot. Results Based on this method an automated synthetic protocol was developed on a TRACERlab FXFC module to synthesise and formulate [11C]SB-216763 at high radioactivies, giving a final radiochemical product of 200 MBq at end-of-synthesis with 97-99% radiochemical purity (n = 5). Conclusions To assess [11C]SB216763 as a PET tracer for GSK-3, studies on healthy rats were performed using a microPET Focus-220, which indicated significant tracer transfer into the brain. [1] P. Cohen et al , Nat. Rev. Drug Disc. 2004, 3, 479. [2] A. Martinez, et al, Med. Res. Rev. 2002, 22, 373. [3] Q. Wang, et al, Oncogene 2005, 25, 43. [4] M. Wang, et al , Bioorg. Med. Chem. Lett. 2011, 21, 245. Research Support UK Medical Research Council